*Clostridium difficile* is the leading cause of antibiotic-associated diarrhea and pseudomembranous colitis. The increasing prevalence and severity of healthcare-associated *C. difficile* infections (CDI) is of great concern \[[@B1]\]. Moreover, emergence and spread of the hypervirulent 027/NAP1/BI strain of *C. difficile* have been reported in North America and Europe \[[@B2]-[@B4]\]. The characteristics of the PCR ribotype 027 strain are production of the *C. difficile* binary toxin (CDT), as well as toxin A/B, and a single nucleotide deletion at position 117 in the *tcdC* gene \[[@B4]\]. The diagnosis of CDI should be based on a combination of symptoms and a positive stool test result for *C. difficile* toxins or toxigenic *C. difficile* \[[@B5]\]. Enzyme immunoassays rapidly detect toxins A and B, but their sensitivity varies greatly among the various products \[[@B6]\]. Toxigenic cultures and cytotoxin assays are considered as gold standard methods for the detection of toxigenic *C. difficile*, but toxigenic cultures that combine anaerobic cultures and detection of toxin A and B production take at least 48 hr to complete. Cytotoxin assays using cultured cells are also time-consuming and costly, making them unsuitable for routine laboratory diagnosis. Therefore, a rapid and more accurate microbiological diagnostic assay is highly needed for providing optimal patient care and controlling the spread of infections in hospitals.

The Xpert *C. difficile* assay (Xpert CD assay; Cepheid, Sunnyvale, CA, USA) is a real-time multiplex PCR assay performed using the GeneXpert Dx system. The assay uses primers targeted to the cytotoxin gene (*tcdB*), binary toxin genes (*cdtA* and *cdtB*), and a single nucleotide deletion at position 117 in the *tcdC* gene. As a result, the Xpert CD assay can detect toxigenic *C. difficile* strains and differentiate *C. difficile* presumptive 027/NAP1/BI. We evaluated the Xpert CD assay for rapidity and accuracy in diagnosing CDI.

A total of 253 consecutive loose stool specimens were collected in a stool specimen container from suspected CDI patients from April to June 2011, in a tertiary hospital. For toxigenic cultures, alcohol-shocked stool specimens were inoculated on *C. difficile* selective agar (CDSA; Becton, Dickinson and Company, Sparks, MD, USA) and incubated at 37℃ in an anaerobic chamber (Forma scientific, Marietta, OH, USA) for 48 hr. Suspected *C. difficile* colonies were used to make a gram-stained smear to observe typical morphology. The species were identified by using the ATB 32A system (bioMérieux, Marcy l\'Etoile, France). The identified *C. difficile* isolates were used to detect *tcdA* repetitive regions, *tcdB* as well as *cdtA* and *cdtB* genes, following the previously described PCR method \[[@B7]\] and using the PCR primers listed in [Table 1](#T1){ref-type="table"}.

Xpert CD assays were performed according to the manufacturer\'s instructions. A stool specimen was transferred to a vial containing a buffer solution by using a sterile swab. The vial was vortexed, and the solution was then transferred to a cartridge. The test was run on the GeneXpert DX module. The results were reported as *C. difficile*-positive 027/NAP1/BI presumptive negative, *C. difficile*-positive 027/NAP1/BI presumptive positive, *C. difficile*-negative, invalid, error, or no result. The test was repeated if the result was \"invalid,\" \"error,\" or \"no result.\" Sequencing of the *tcdC* gene was performed on isolates that were positive for the presumptive 027/NAP1/BI strain. PCR ribotyping and *tcdC* sequencing were performed in accordance with previously described methods \[[@B8], [@B9]\] for isolates that tested positive for binary toxin genes in the Xpert CD assay in order to confirm the results.

VIDAS *C. difficile* A & B assays (VIDAS CDAB assay; bioMérieux) were performed according to the manufacturer\'s instructions. Test results are presented as positive, negative, or equivocal for toxins A and/or B. Specimens with equivocal results were retested once.

By anaerobic culture, 55 of 253 (21.7%) specimens yielded *C. difficile* isolates. Of these, 49 (19.4%) isolates were confirmed to be *tcdB*-positive ([Table 2](#T2){ref-type="table"}).

The Xpert CD assay detected *tcdB* in all 49 isolates identified as *tcdB*-positive by toxigenic culture (sensitivity 100%, [Table 3](#T3){ref-type="table"}). For 8 specimens that tested positive in the Xpert CD assay but were negative upon toxigenic culture, an enrichment culture was performed using cycloserine-cefoxitin fructose broth supplemented with 0.1% sodium taurocholate (TCCFB). Four of these eight specimens yielded a positive result for toxigenic *C. difficile* ([Table 4](#T4){ref-type="table"}). On the basis of analyses of other samples from the same patients, we suspect that at least 2 samples were contaminated with residual DNA \[[@B10]\]. In 3 undetermined cases, possible explanations for the discrepant results are residual DNA from prior CDI, false-positive PCR result, or true-positive PCR result.

Compared to the toxigenic culture, the sensitivity, specificity, and positive and negative predictive values were 100%, 94.6%, 83.1%, and 100%, respectively, for the Xpert CD assay, and 40.8%, 98.0%, 100%, and 88.9%, respectively, for the VIDAS CDAB assay ([Table 3](#T3){ref-type="table"}). The overall agreement between the Xpert CD assay and toxigenic culture was 95.7%. Data from the enrichment culture were not included in the calculation of sensitivity, specificity, and positive and negative predictive values. One \"error\" case of the Xpert CD assay and 8 \"equivocal\" cases of the VIDAS CDAB assay were included in the calculation of assay performance ([Table 2](#T2){ref-type="table"}).

Binary toxin genes (*cdtA* and *cdtB*) were detected in 5 specimens by the Xpert CD assay, and 1 of them showed a 027/NAP1/BI presumptive positive result. The binary toxin genes were confirmed by toxin gene-specific PCR, PCR ribotyping, and *tcdC* sequencing. Four (including one 027/NAP1/BI presumptive positive isolate) of the 5 isolates revealed positive results for binary toxin genes. In addition, all 4 isolates showed an identical pattern to that of ribotype 078 and no deletion at position 117 of the *tcdC* gene. All ribotype 078 strains showed a 39-base pair deletion and a point mutation at position 184 in the *tcdC* gene \[[@B11]\].

Similar to a previous study, the evaluation of the usefulness of the Xpert CD assay for screening for the 027 strain was limited in this study due to the low prevalence of binary toxin-producing *C. difficile* strains (3.8% to 7.1%) and PCR ribotype 027 (0.6%) in Korea \[[@B12], [@B13]\]. A previously published study reported that the agreement between the Xpert CD assay and PCR-ribotyping was 93% \[[@B10]\]. Other studies reported discordant results for the presumptive 027/NAP1/BI strain between the Xpert CD assay and conventional typing and sequencing \[[@B14], [@B15]\]. These authors reported 1 ribotype 053 strain \[[@B15]\], 1 strain similar to the 078 strain \[[@B14]\], and 6 strains of unknown type. Ribotype 078 is the most frequent type present as a binary toxin-positive strain in Korea \[[@B12], [@B13]\]. Therefore, results of the presumptive 027/NAP1/BI strain must be interpreted with caution, particularly in Korea, where the prevalence of ribotype 027 is low.

The most significant advantage of the Xpert CD assay is its rapidity and simplicity. A loose stool specimen can be directly used, and the assay takes only 45 min.

In conclusion, the Xpert CD assay is a reliable method for detecting toxigenic *C. difficile* directly from stool specimens and provides greater sensitivity than an enzyme immunoassay.
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###### 

Sequences of the PCR primers used in this study

![](alm-32-355-i001)

Abbreviations: *tcdA* rep, toxin A gene repetitive region; *tcdB*, toxin B gene; *cdtA* and *cdtB*, binary toxin genes.

###### 

Evaluation of Xpert *Clostridium difficile* and VIDAS *Clostridium difficile* A & B assays for the detection of toxigenic *Clostridium difficile* isolates
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^\*^One presumptive 027/NAP1/BI strain identified as ribotype 078 on PCR ribotyping as well as a 39-base pair deletion and a point mutation at position 184 in *tcdC*; ^†^Four specimens showed positive results by enrichment culture; ^‡^One \"error\" in the Xpert CD assay: no growth on anaerobic culture and negative on VIDAS-CDAB.

Abbreviations: Xpert CD, Cepheid Xpert *Clostridium difficile* assay; VIDAS-CDAB, VIDAS *Clostridium difficile* Toxin A&B assay; A, toxin A; B, toxin B; CDT, *C. difficile* binary toxin; 027, presumptive 027/NAP1/BI strain.

###### 

Assay performance of Xpert *Clostridium difficile* and VIDAS *Clostridium difficile* A & B assays for the detection of toxigenic *Clostridium difficile* isolates compared with toxigenic culture

![](alm-32-355-i003)

^\*^Sensitivity, specificity, PPV, and NPV are calculated as follows (×100): sensitivity, (number of true-positive assay results)/(sum of toxigenic culture-positive results); specificity, (number of true-negative assay results)/(sum of toxigenic culture-negative results); PPV, (number of true-positive assay results)/(sum of true-positive and false-positive assay results); NPV, (number of true-negative assay results)/(sum of true-negative and false-negative assay results).

Abbreviations: Xpert CD, Xpert *Clostridium difficile* assay; VIDAS-CDAB, VIDAS *Clostridium difficile* A & B assay; PPV, positive predictive value; NPV, negative predictive value.

###### 

Discordant results and further analysis of Xpert *Clostridium difficile* and toxigenic culture^\*^
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^\*^All samples with initially no growth on anaerobic culture and *Clostridium difficile*-positive 027/NAP1/BI presumptive negative on Xpert CD assay; ^†^False-positive PCR, residual DNA, or true-positive PCR.

Abbreviations: Xpert CD, Cepheid Xpert *Clostridium difficile* assay; VIDAS-CDAB, VIDAS *Clostridium difficile* Toxin A & B assay.
